Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Gully, Christopher P ^a,b   Zhang, Fanmao ^a,b   Chen, Jian ^a   Yeung, James A ^a   Velazquez Torres, Guermarie ^a,b   Wang, Edward ^a,b   Yeung, Sai Ching J ^a   Lee, Mong Hong ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[3 [4 [5 [2 (3 FLUOROANILINO) 2 OXOETHYL] 1H PYRAZOL 3 YLAMINO] 7 QUINAZOLINYLOXY]PROPYL](ETHYL)AMINO]ETHYL DIHYDROGEN PHOSPHATE; 2 [[3 [4 [5 [2 (3 FLUOROANILINO) 2 OXOETHYL] 1H PYRAZOL 3 YLAMINO] 7 QUINAZOLINYLOXY]PROPYL](ETHYL)AMINO]ETHYL DIHYDROGEN PHOSPHATE HYDROXYQUINAZOLINE PYRAZOL ANILIDE; AURORA B KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; 2 ((3 ((4 ((5 (2 ((3 FLUOROPHENYL)AMINO) 2 OXOETHYL) 1H PYRAZOL 3 YL)AMINO)QUINAZOLIN 7 YL)OXY)PROPYL)(ETHYL)AMINO)ETHYL DIHYDROGEN PHOSPHATE; 2-((3-((4-((5-(2-((3-FLUOROPHENYL)AMINO)-2-OXOETHYL)-1H-PYRAZOL-3-YL)AMINO)QUINAZOLIN-7-YL)OXY)PROPYL)(ETHYL)AMINO)ETHYL DIHYDROGEN PHOSPHATE; ANTINEOPLASTIC AGENT; AURORA KINASE; ORGANOPHOSPHATE; POLYUBIQUITIN; PROTEASOME; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; QUINAZOLINE DERIVATIVE;

ANEUPLOIDY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; MITOSIS; MOUSE; NONHUMAN; POLYPLOIDY; TREATMENT RESPONSE; TUMOR GROWTH; ANIMAL; BREAST TUMOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; METABOLISM; METASTASIS; PATHOLOGY; PROTEIN PROCESSING; UBIQUITINATION;

ANEUPLOIDY; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; G2 PHASE; HUMANS; MICE; MITOSIS; NEOPLASM METASTASIS; PHOSPHORIC ACID ESTERS; POLYPLOIDY; POLYUBIQUITIN; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; QUINAZOLINES; TUMOR STEM CELL ASSAY; UBIQUITINATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77649305739     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-42     Document Type: Article

References (28)

1. Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, Komatsu N, Bandobashi K, Togitani K, Koeffler HP, et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 2007, 110:2034-2040. 10.1182/blood-2007-02-073700, 17495131.
2. Tao Y, Zhang P, Girdler F, Frascogna V, Castedo M, Bourhis J, Kroemer G, Deutsch E. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152. Oncogene 2008, 27:3244-3255. 10.1038/sj.onc.1210990, 18084327.
3. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 2003, 22:451-464. 10.1023/A:1023789416385, 12884918.
4. Fu J, Bian M, Jiang Q, Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007, 5:1-10. 10.1158/1541-7786.MCR-06-0208, 17259342.
5. Ducat D, Zheng Y. Aurora kinases in spindle assembly and chromosome segregation. Exp Cell Res 2004, 301:60-67. 10.1016/j.yexcr.2004.08.016, 15501446.
6. Lens SM, Medema RH. The survivin/Aurora B complex: its role in coordinating tension and attachment. Cell Cycle 2003, 2:507-510.
7. Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, Brady MC, Bigley A, Brown E, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 2007, 13:3682-3688. 10.1158/1078-0432.CCR-06-2979, 17575233.
8. Hsu JY, Sun ZW, Li X, Reuben M, Tatchell K, Bishop DK, Grushcow JM, Brame CJ, Caldwell JA, Hunt DF, et al. Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes. Cell 2000, 102:279-291. 10.1016/S0092-8674(00)00034-9, 10975519.
9. Vader G, Cruijsen CW, van Harn T, Vromans MJ, Medema RH, Lens SM. The chromosomal passenger complex controls spindle checkpoint function independent from its role in correcting microtubule kinetochore interactions. Mol Biol Cell 2007, 18:4553-4564. 10.1091/mbc.E07-04-0328, 2043551, 17699588.
10. Evans RP, Naber C, Steffler T, Checkland T, Maxwell CA, Keats JJ, Belch AR, Pilarski LM, Lai R, Reiman T. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol 2008, 140:295-302. 10.1111/j.1365-2141.2007.06913.x, 18076711.
11. Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, Mortlock A, Keen N, Taylor SS. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 2003, 161:267-280. 10.1083/jcb.200208091, 2172902, 12719470.
12. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004, 4:927-936. 10.1038/nrc1502, 15573114.
13. Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y. Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res 1999, 59:2041-2044.
14. Nadler Y, Camp RL, Schwartz C, Rimm DL, Kluger HM, Kluger Y. Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Cancer Res 2008, 14:4455-4462. 10.1158/1078-0432.CCR-07-5268, 18628459.
15. Cochran AG. Aurora A: target invalidated?. Chem Biol 2008, 15:525-526. 10.1016/j.chembiol.2008.06.002, 18559262.
16. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. Embo J 1998, 17:3052-3065. 10.1093/emboj/17.11.3052, 1170645, 9606188.
17. Girdler F, Sessa F, Patercoli S, Villa F, Musacchio A, Taylor S. Molecular basis of drug resistance in aurora kinases. Chem Biol 2008, 15:552-562. 10.1016/j.chembiol.2008.04.013, 18559266.
18. Mortlock AA, Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann JJ, Warin N, Renaud F, De Savi C, Roberts NJ, et al. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem 2007, 50:2213-2224. 10.1021/jm061335f, 17373783.
19. Laronga C, Yang HY, Neal C, Lee MH. Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem 2000, 275:23106-23112. 10.1074/jbc.M905616199, 10767298.
20. Jerome L, Alami N, Belanger S, Page V, Yu Q, Paterson J, Shiry L, Pegram M, Leyland-Jones B. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. Cancer Res 2006, 66:7245-7252. 10.1158/0008-5472.CAN-05-3555, 16849573.
21. Wang LH, Yang XY, Zhang X, Mihalic K, Fan YX, Xiao W, Howard OM, Appella E, Maynard AT, Farrar WL. Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor. Nat Med 2004, 10:40-47. 10.1038/nm969, 14702633.
22. Goto H, Yasui Y, Nigg EA, Inagaki M. Aurora-B phosphorylates Histone H3 at serine28 with regard to the mitotic chromosome condensation. Genes Cells 2002, 7:11-17. 10.1046/j.1356-9597.2001.00498.x, 11856369.
23. Wei Y, Yu L, Bowen J, Gorovsky MA, Allis CD. Phosphorylation of histone H3 is required for proper chromosome condensation and segregation. Cell 1999, 97:99-109. 10.1016/S0092-8674(00)80718-7, 10199406.
24. Hirota T, Lipp JJ, Toh BH, Peters JM. Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatin. Nature 2005, 438:1176-1180. 10.1038/nature04254, 16222244.
25. Yasui Y, Urano T, Kawajiri A, Nagata K, Tatsuka M, Saya H, Furukawa K, Takahashi T, Izawa I, Inagaki M. Autophosphorylation of a newly identified site of Aurora-B is indispensable for cytokinesis. J Biol Chem 2004, 279:12997-13003. 10.1074/jbc.M311128200, 14722118.
26. McKenzie T, Liu Y, Fanale M, Swisher SG, Chada S, Hunt KK. Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells. Surgery 2004, 136:437-442. 10.1016/j.surg.2004.05.022, 15300212.
27. Warburton C, Dragowska WH, Gelmon K, Chia S, Yan H, Masin D, Denyssevych T, Wallis AE, Bally MB. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res 2004, 10:2512-2524. 10.1158/1078-0432.CCR-03-0244, 15073131.
28. Osborne CK, Hobbs K, Clark GM. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 1985, 45:584-590.